他汀类药物对充血性心力衰竭患者的短期临床疗效评价及对患者心功能指标变化的影响

摘要

目的：探讨阿托伐他汀对充血性心力衰竭（CHF）患者的短期临床疗效，并评估对其心功能的影响，为临床治疗提供依据。方法：选择2015年5月-2016年1月本院CHF患者200例，随机分为对照组和研究组，两组各100例。对照组患者进行常规治疗，研究组应用阿托伐他汀治疗40 mg/次，口服，连续用药治疗2周。观察患者临床疗效、应用超声评估患者心功能变化及6 min步行试验（6-MWT）结果。结果：研究组患者显效率为75.00%（75/100），高于对照组的65.00%（65/100），差异有统计学意义（P<0.05）；研究组患者心功能评分为（2.04±0.15）分，低于对照组的（2.71±0.13）分，差异有统计学意义（P<0.05）；研究组患者治疗后每搏心输出量（SV）、左心室射血分数（LVEF）、心脏指数（CI）、外周血管阻力指数（SVRI）和6-MWT分别为（4.81±0.12）L/min、（48.53±6.15）%、（271.53±14.60）dyn/s、（2.89±0.15）L/（min·m2）和（278.29±12.41）m，均高于对照组治疗后（4.20±0.16）L/min、（45.82±5.96）%、（259.40±15.29）dyn/s、（2.50±0.14）L/（min·m2）和（103.69±10.14）m，且两组治疗后均高于治疗前，差异均有统计学意义（P<0.05）。结论：应用阿托伐他汀治疗CHF患者具有较好的短期临床疗效，能够显著改善患者心功能及预后，值得临床推广应用。%Objective:To explore the short-term clinical curative effect of atorvastatin for the patients with congestive heart failure (CHF),and to evaluate the effect on the cardiac function.And so as to provide evidence for clinical treatment.Method:A total of 200 CHF patients were selected in the hospital from May 2015 to January 2016.And they were randomly divided into the control group and the research group,100 cases in each group.The control group were treated with conventional therapy,the research group was treated with Atorvastatin 40 mg/times,oral,continuous treatment for 2 weeks.Observed the clinical efficacy,cardiac function change application of ultrasound and 6 min walking test (6-MWT) results.Result:The markedly effective rate of the study group was 75.00%(75/100),higher than that of the control group 65.00%(65/100),the difference was statistically significant (P<0.05),cardiac function of patients in the study group was(2.04±0.15),lower than the control group(2.71±0.13),the difference was statistically significant (P<0.05).The each stroke volume(SV), left ventricular ejection fraction(LVEF),cardiac index(CI),peripheral vascular resistance index (SVRI)and 6-MWT of the study group after treatment were (4.81±0.12)L/min,(48.53±6.15)%,(271.53±14.60)dyn/s, (2.89±0.15)L/(min·m2),(278.29±12.41)m,higher than the control group after treatment(4.20±0.16)L/min, (45.82±5.96)%,(259.40±15.29)dyn/s,(2.50±0.14) L/(min·m2)and (103.69±10.14)m,and two groups after treatment were higher than those of before treatment,the differences were statistically significant(P<0.05). Conclusion:Atorvastatin treatment the patients with CHF was better short-term clinical efficacy,which can significantly improve the patient’s cardiac function and prognosis.And it is worthy of clinical application.